Search

Search Constraints

You searched for: Author/Creator Hurkmans, Daan P.

Search Results

1. A prospective cohort study on the pharmacokinetics of nivolumab in metastatic non-small cell lung cancer, melanoma, and renal cell cancer patients. Issue 1 (19th July 2019)

2. Associations between patient and disease characteristics and severe adverse events during immune checkpoint inhibitor treatment: An observational study. (October 2022)

3. CD45RA+CCR7− CD8 T cells lacking co-stimulatory receptors demonstrate enhanced frequency in peripheral blood of NSCLC patients responding to nivolumab. Issue 1 (8th June 2019)

4. Correlation between nivolumab exposure and treatment outcomes in non–small-cell lung cancer. (March 2019)

5. Donor-derived cell-free DNA detects kidney transplant rejection during nivolumab treatment. Issue 1 (12th July 2019)

6. Granzyme B is correlated with clinical outcome after PD-1 blockade in patients with stage IV non-small-cell lung cancer. Issue 1 (26th May 2020)

7. High-intensity statins are associated with improved clinical activity of PD-1 inhibitors in malignant pleural mesothelioma and advanced non-small cell lung cancer patients. (February 2021)

8. Molecular data show conserved DNA locations distinguishing lung cancer subtypes and regulation of immune genes. (August 2020)

9. Prospective real-world study on the pharmacokinetics of pembrolizumab in patients with solid tumors. Issue 6 (4th June 2021)

10. The prognostic value of weight and body composition changes in patients with non‐small‐cell lung cancer treated with nivolumab. Issue 3 (5th May 2021)